Sperimentazioni cliniche

Amiloidosi AL
A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

Protocol AC-012-EU v. 1.3

di prossima attivazione:

    1. Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis
    1. A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis
    1. An open-label, phase 1/2 study of melflufen and dexamethasone for patients with AL amyloidosis following at least one prior line of therapy